Medidata Supports White House Cancer Moonshot Effort with its Patient Cloud Technologies

New York–July 27, 2022–Medidata, a Dassault Systèmes company, is supporting the White House Cancer Moonshot initiative by working with the National Cancer Institute (NCI) to enroll patients in the Cancer Moonshot Biobank. The Biobank is a project designed to better understand how cancer develops and grows, and why some cancers stop responding to treatment. People with cancer are asked to donate tumor tissue, blood samples, and health data to find discoveries that improve cancer treatments and increase survival.

Medidata, Theradex Oncology, and NCI are helping enroll patients in the Biobank across more than 100 clinical sites in the U.S. This team works together to engage and educate study volunteers, accurately and securely collect patient information in the clinical trial, and enroll patients in the project. The enrollment process includes clinical site staff providing orientation content and related HIPAA (Health Insurance Portability and Accountability Act privacy law) documents to the patient for education and eSignature. 

These activities are part of the White House Cancer Moonshot initiative, which has set a goal of reducing the cancer death rate by 50% over the next 25 years, and improving the experience of people and their families living with and surviving cancer.

“We won’t reach the goals of the Cancer Moonshot without gathering a rich set of data for researchers, and that requires attracting a diverse and expansive patient population to participate,” said Peter Clark, director, NCI Rave Development at Theradex Oncology, a CRO providing cancer clinical trial services. “Once a patient has agreed to participate, keeping them comfortable and facilitating an easy enrollment are important, and we appreciate the assistance we have received from the Medidata team in supporting this.” 

The Cancer Moonshot Biobank relies on Medidata’s Patient Cloud and Rave solutions, including eConsent and Rave EDC (electronic data capture). eConsent is an innovative, regulatory-compliant, patient-friendly, electronic consent system for clinical trials. Rave EDC (electronic data capture) is the most advanced, robust, and secure system for clinical trial site, patient, and lab data capture and management.

“We are proud to be part of supporting this important initiative,” said David Geismar, senior vice president, Professional Services at Medidata. “Helping enroll patients with eConsent and managing patient data with Rave EDC are important pieces of the overall  Cancer Moonshot Biobank effort to accelerate progress in treating cancer and helping patients with cancer live longer.”

Medidata currently supports more than 2,000 clinical trials in the government, academic, and not-for-profit sectors. Medidata’s commitment to these sectors extends from providing the industry-leading Rave EDC to innovative patient-facing technologies like eConsent and more.

To learn more about the Cancer Moonshot Biobank and how to participate, visit

Medidata is a wholly-owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 2,000+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers.  Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.


Tom Paolella
Senior Director, Corporate Communications & Affairs

Paul Oestreicher
External Communications Director